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Abstract
Purpose: The purpose of this study was to explore the risk factors for breast cancer and establish the expression rate of IGF-
2 in female patients.
Methods: A case control study with 500 people in case group and 500 people in control group. A self-administered
questionnaire was used to investigate risk factors for breast cancer. All cases were interviewed during a household survey.
Immune-histochemical method was used to inspect the expression of IGF-2 in different tissues (benign breast lesions, breast
cancer and tumor-adjacent tissue).
Results: Multivariate adjusted odds ratios and 95% confidence intervals were calculated using unconditional logistic
regression. High body mass index (OR=1.012,95%CI=1.008–1.016), working attributes (OR=1.004, 95%CI=1.002=1.006),
long menstrual period (OR=1.007, 95%CI=1.005–1.009), high parity OR=1.003, 95%CI=1.001–1.005) , frequent artificial
abortion (OR=1.004, 95%CI=1.001–1.005), family history of cancer (OR=1.003, 95%CI=1.000–1.005), period of night shift
(OR=1.003, 95%CI=1.001–1.006), live in high risk environment (OR=1.005, 95%CI=1.002–1.008), and family problems
(OR=1.010, 95%CI=1.005–1.014) were associated with increased risk for breast cancer. In this study, good sleeping status,
positive coping strategies, subjective support, and utility degree of social support were associated with reduced risk for
breast cancer (OR=0.998, 0.997, 0.985, 0.998 respectively; 95%CI=0.996–1.000, 0.994–1.000, 0.980–0.989, 0.996–1.000,
respectively). In benign breast lesions, breast cancer and tumor-adjacent tissue, IGF-2 was mainly expressed in the
cytoplasm, but its expression rate was different (p,0.05).
Conclusions: The incidence of breast cancer is a common result of multiple factors. IGF-2 is involved in the development of
breast cancer, and its expression varies in different tissues (benign breast lesions, breast cancer and tumor-adjacent tissue).
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Introduction
Breast cancer is the most common cancer among women with
an estimated 1.38 million new cases diagnosed in 2008 (23% of all
cancers), and ranks second overall (10.9% of all cancers)
worldwide [1]. Large differences in rates of the disease exist
between countries, with higher rates in developed countries
(America and West Europe) and lower rates in developing
countries (Asia). The incidence of breast cancer in china is on
the rise. The rise is probably due to lifestyle changes in women and
lack of awareness programs. It is rapidly becoming the number
one cancer in females [2].The risk factors for BC include early age
of menarche, delayed menopause, contraceptive use, hormonal
replacement therapy, above-average body mass index, exposure to
environmental pollutants, smoking, and use of alcohol [3–5].
Insulin-like growth factors (IGFs) are associated with the
development and progression of breast cancer. IGF-1 and IGF-2
transmit their signals through two paralagous receptor proteins
located in the plasma membrane: the type 1 IGF receptor and the
insulin receptor (IGF receptors). High circulating IGF-1 concen-
trations and low blood IGF binding protein concentrations are risk
factors for several types of cancer including breast cancer [6–8].
Some studies indicate that IGF-2 activates ER-a and ER-b and
modulates their translocation to the nucleus, membrane organelles
and the mitochondria [9]. The purpose of the study was therefore
to explore risk factors for breast cancer development and to
identify IGF-2 expression rate in invasive breast cancer in women
of Wuhan city.
Methods
Subjects
A hospital-based case-control study population was recruited
from March 2007 to June 2009 in Wuhan city to investigate risk
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36497factors of breast cancer (BC). A total of 1000 women were enrolled
in the study. Eligible cases were women aged 23–80 years
diagnosed with insitu or invasive breast cancer during the studying
period. BC patients enrolled in the study were restricted to women
identified in the four major public hospitals in the city. These
hospitals were Tongji hospital, Union hospital, Hubei Province
Cancer Hospital and Wuhan Central Hospital. All cases were
histologically confirmed. Upon histological confirmation of diag-
nosis, only those cases without previous treatment for BC were
included in the study. The tumor stage was determined according
to the TNM system [10]. Among the 505 eligible cases identified
during the study period, 3 refused to participate, 2 died before the
interview. Majority of breast cancers were in premenopausal stage,
and the most common type was IDC (infiltrating ductal
carcinoma).
Controls were women from the general population without
breast cancer and mental illness, who were matched by age (63-
years) to an equal number of cases. Controls were randomly
selected from the general female population using the Wuhan
Resident Registry. Among the 554 eligible controls identified, 39
refused to participate, 15 could not be contacted for interviews. All
study participants had to be residents of the Wuhan city for at least
5years.
All 1000 women in the study completed a self-administered
questionnaire. Information on demography, smoking, use of
alcohol, sleeping status, living environment, reproductive history
and other breast cancer risk factors was collected. Interviews
included household survey and hospitals interviews. All partici-
pants were interviewed with LES, TCSQ, and SSRS.
In order to establish the expression of IGF-2, we selected 63
new BC cases in 500 breast cancer cases. The cases were selected
in 2009, and they had not received any treatment such as
chemotherapy or radiation before surgery. Among the 63 cases, 52
cases had infiltrating ductal carcinoma (IDC), 8 cases had duct cell
carcinoma insitu (DCIS), and 3 cases had infiltrating lobular
carcinoma (ILC). We analysed the expression rate of IGF2 in the
three groups of tissues. The groups were; (1) Sixty three
pathological samples of invasive breast cancer derived from case
group. (2) Matched adjacent normal tissue 5 cm away from the
tumors and (3) 70 breast benign lesions derived from the case
group.
Ethical consideration
The study was approved by Wuhan Public Health Ethical
Committee. Permission to conduct the study was also obtained
from the Administrative council of the four hospitals, where the
study subjects were enrolled. Further consent was obtained from
the Management of Wuhan City Council. Informed written
consent was also obtained from all participants of the study.
Immuno-histochemical (IHC) method
Anti-IGF2 antibody (H-103) was commercially available from
Santa Cruz Company, (Rabbit, and #sc-5622). Slides were
deparaffinized using xylene and graded ethyl alcohols and then
rinsed in water. After 3%hydrogen peroxidase block for 30 min-
utes, antigen retrieval was performed by boiling slides in antigen
retrieval solution in a microwave oven at half maximum power for
4 min *6times, followed by a 30-minutes cool-down and rinsing in
wash buffer. Slides were then sequentially treated with the
following reagents in a humidified chamber at room temperature:
10% normal goat serum for 30 minutes, anti-IGF2 antibody
overnight, secondary antibody for 30 minutes, signal amplification
and chromogen development for 30 minutes each (wash buffer
steps were included between each step). Stained slides were then
counterstained with hematoxylin. Each run included appropriate
controls.
Statistical analysis
Demographic characteristics were contrasted by case-control
status. Characteristics of the participating cases and controls were
compared by using t test for continuous variables, and x2 test for
continuous variables. Unconditional logistic regression was used to
estimate OR (odd ratios) and 95% CI (95% confidence intervals)
for the association of life style and breast cancer incidence.
These factors were evaluated by unconditional regression model
in order to find the association between them and the risk of breast
cancer development. All statistical tests were two-sided. P value
less than 0.05 was considered statistically significant. The SPSS
version 18.0 statistical software package was used to analyze the
data.
Results
Sociodemographic characteristics and reproductive
variables
Table 1 shows the frequency distributions of sociodemographic
and study variables for cases and controls. As a result of frequency
matching, cases and controls were similar with respect to
likelihood of age and educational levels (p.0.05 for all compar-
isons). High BMI was associated with increased incidence of breast
cancer (p,0.05). Only 32.9% women chose breast feeding for
their children in cases as compared to 54.4% in controls. The
difference was statistically significant (P,0.05). Controls had late
age of menarche, younger age at first live birth, a greater
percentage of breastfeeding, high parity, a high frequency of
abortion and were less likely to have a personal history of breast
fibroadenoma than cases. The difference of two groups was
statistically significant (p,0.001).
Cancer risk factors
Step conditional logistic regression showed that high BMI,
working conditions, delayed menopause, high parity, increased
number of induced abortion, family history of breast cancer, many
years of night shift work, living environment with high-risk factors,
family problems, and a higher total score of social life events were
associated with increased likelihood of breast cancer development
(P,0.05). Good sleeping behaviour, positive coping strategies, and
higher score of subjective support and utility degree of social
support were associated with decreased likelihood of breast cancer
development (P,0.05) (Table 2).
Clinical foundation data in IHC experiment
Age. 63 cases and 70 controls were included in the immune-
histochemical experiment and their ages were well matched (age/
yr:49.169.76 in cases versus 49.0610.09 in controls, t=0.07,
P=0.943). Maximum age and minimum age in both groups were
the same. The oldest was 71 years old, and the youngest was 25
years old.
Post-menopausal women. In invasive breast cancer group,
there were 42(66.7%) post-menopausal cases. While in benign
breast lesions group there were 47 (67.1%) post-menopausal cases.
There was no statistical difference between the two groups of
subjects in terms menopausal status (P=0.9535) (Table 3).
Body mass index (BMI). In the 63 cases with invasive breast
cancer, the mean body mass index was 22.762.65 (kg/m
2). The
maximum (BMI) was 29.7 kg/m
2, and the minimum was 16.0 kg/
m
2. In the 70 cases with breast benign lesion, the mean body mass
index was 21.462.09 (kg/m
2). The maximum (was 27.8 kg/m
2,
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2. The difference of two groups
was statistically significant (t=3.13, P=0.0022) (data not included
in the tables).
Histological grades. According to the standard of histolog-
ical grade, 21 cases were classified into grade I, 34 into grade II,
and 8 cases into grade III. There were 25 cases without the
metastasis of lymph node in the invasive breast cancer. However,
there were also 38 cases with the metastasis of lymph node and
other tissues. In 63 cases of invasive breast cancer, 41 cases had
tumors that were more or equal to 3 cm in size, the remaining 22
cases the tumors were less than 3 cm. Estrogen receptor was found
positive in 33 cases. In benign breast lesions patients, 57 cases had
tumors less than 3 cm (data not included in the tables).
IGF-2 expression. In benign breast lesions, breast cancer
and tumor-adjacent tissue, IGF-2 was mainly expressed in the
cytoplasm, but in different tissues the expression was different
(p,0.05).In 63 cases of breast invasive ductal cancer, 26 cases
were positive for IGF-2.While 7 of 59 cases of breast cancer-
adjacent tissue, the expression of IGF -2 was positive, but most of
them were weakly positive. In 17 of 70 cases of benign breast
lesion patients, IGF-2 was positive but its expression rate was lower
than in invasive breast cancer. (See Fig. 1). The expression of IGF-
2 in three types of tissue was significant (P=0.0001). The
expression level of IGF -2 in invasive ductal carcinoma was
higher than in tumor-adjacent tissue and the difference was
statistically significant (x2 =13.35, P=0.0003). In benign breast
lesions, however, the expression rate of IGF 2 was not statistically
different from breast cancer and the adjacent tissues (x2 =4.37 and
3.26 respectively; P=0.0365 and 0.0709 respectively). (Table 4)
The expression of IGF- 2 in breast cancer was not related to
patients’ age, menopause or tumor size. In cases with different
ages, menopausal status and different sizes of primary lesion, the
expression of IGF-2 was not statistically different (P.0.05. A
significant relationship was observed, however, among breast
cancer with different histological grade, with or without lymph
node metastasis and with or without oestrogen receptor positivity
in the expression of IGF-2, and the difference was statistically
significant (x2 =14.17, 5.10, 7.60 respectively; P values 0.0002,
0.0239, 0.0058 respectively). Rank correlation analysis showed
that the expression of IGF-2 in breast cancer tissue was positively
correlated to tumor histological grade, lymph node metastasis and
the expression of oestrogen receptor (Table 5).
Discussion
BC is a major public health problem affecting millions of
women worldwide. With industrialization and urban development,
delayed or reduced fertility, increased longevity and altered
lifestyle, the incidence of BC is rising steadily even in developing
countries. Analysis of data showed that most breast cancer patients
were between 40 and 60 years old. The reason behind this is
gradual decrease in ovarian function which is common during this
period and increase in anterior pituitary activities which result in
more estrogen being produced by adrenal cortex, and conse-
quently excessive proliferation of mammary gland epithelial cells.
It is therefore important for health workers to encourage women
who are more than 30 years old to have regular breast
examination once a year.
The results of the study show that the risk of breast cancer
development increases significantly with increasing level of body
mass index (BMI). The association is clear between high BMI and
the increasing Insulin and IGFs. Insulin promotes cancer cell
growth, IGFs stimulate cell turnover in most body tissues. [11–12].
Significant epidemiological studies suggest that high fat intake,
Table 1. Sociodemographic characteristics and reproductive
health variables among cases and Controls.
Cases(n=500) Controls(n=500) P value
n% n%
Age
#30 12 2.4 14 2.8
31,40 68 13.6 65 13.0
41,50 201 40.2 196 39.2
51,60 153 30.6 158 31.6
61,70 40 8.0 38 7.6
$71 26 5.2 29 5.8
Educational level 0.977
Elementary school or below 88 17.4 91 18.2
Junior high school 169 33.8 159 31.8
Senior high school 116 23.2 119 23.8
Junior college 71 14.2 73 14.6
College or above 56 11.2 58 11.6
Body mass index ,0.0001
,18.5 23 4.6 26 5.2
18.5,22.9 217 43.4 392 78.4
23,24.9 209 41.8 76 15.2
.25 51 10.2 6 1.2
Age of menarche
#12 162 32.4 78 15.6 ,0.0001
12,14 219 43.8 223 44.6
$15 119 23.8 199 39.8
Parity ,0.001
nulliparous 16 3.2 17 3.4
1 231 46.2 151 30.2
2 224 44.8 253 50.6
3 26 5.2 61 12.2
4
+ 3 0.6 18 3.6
Age at first live birth years ,0.001
#20 14 2.8 13 2.7
21,24 19 3.9 29 6.0
25,29 193 39.9 215 44.5
30,34 208 43.0 221 45.7
$35 50 10.4 5 1.1
Number of abortion ,0.001
0 7 41 4 . 8 9 81 9 . 6
1 131 26.2 276 55.2
2 224 44.8 82 16.4
3 46 9.2 34 16.8
4
+ 25 5.0 10 2.0
Lactation situation ,0.001
Breast feeding 159 32.9 263 54.4
Mixed feeding 248 51.2 170 35.2
Artificial feeding 77 15.9 50 10.4
Benign breast disease ,0.001
Yes 344 68.8 57 11.4
No 156 31.2 443 88.6
doi:10.1371/journal.pone.0036497.t001
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14]. It is therefore important to advise women to follow good
eating habits by eating nutritious food which is low in fats and to
do regular body exercises in order to prevent obesity.
The relationship between breast cancer and occupation is under
discussion. Occupation as analysed by the multivariate conditional
logistic regression in this research revealed that the difference in
work pressure and working conditions between various occupa-
tions can explain part of this phenomenon. A related study also
found an association between night shift work and breast cancer
risk among women [15]. In a large prospective cohort study which
included 78,562 women from the Nurses’ Health Study, found an
increased incidence of breast cancer among postmenopausal
women who had worked for 30 or more years on rotating night
shifts (RR=1.36; 95% CI=1.04–1.78) [16]. It is important for
Policy makers to ensure that work policies are made or amended
to limit the number of night shifts work for women.
Numerous studies confirm that a small age of menarche and
more years of menstruation are associated with high risk for breast
cancer development. Literature also indicates that women whose
menstrual age is more than 40 years have a double risk for breast
cancer development as compared to women whose menstrual age
is less than 30 years [17]. According to a previous research, early
abortion was found as a risk factor for breast cancer development.
In this study, menstrual period, parity and number induced
abortion were analysed by multivariate logistic regression model,
which revealed that they are risk factors for breast cancer.
Therefore, pregnancy during marriage should be recommended
and unwanted pregnancy should be prevented by encouraging
women to use family planning methods. Those who have had
induced abortion should be screened regularly and encouraged to
do self-breast examination.
Analysis of data by logistic regression model in this study
showed that lifestyle changes can have an effect on the risk of
developing breast cancer; this is also supported by several lines of
evidence in this research. Good quality of sleep is a protective
factor, while longer working period of night shift in a year was
entered in logistic regression mode as a risk factor. The body
produces melatonin during night, which protects deoxyribonucleic
acid (DNA) from being damaged by oxide in the body;
simultaneously it can inhibit the production of estrogen. Long-
term night shift will disrupt the rhythm of life, and then will
increase the level of circulating estrogen, consequently inhibiting
the body’s tumor suppressor mechanism [18].
It can therefore be seen that the more women take negative
response to breast cancer risk factors, the more susceptible they are
to breast cancer. Subjective support and the high use of social
support reduce the incidence of breast cancer [15]. Metastatic
breast cancer patients with low cortisol concentrations may take
better social support. In other words, they have more healthy
Table 2. Multiple conditional logistic regression analysis for the risk factors of breast cancer.
Factors b Standard error OR 95%CI x
2 P
Body mass index 0.0120 0.00187 1.012 1.008–1.016 23.8670 ,.0001
Working attributes 0.00386 0.000998 1.004 1.002–1.006 7.3274 0.0068
Number of days for menses 0.00672 0.00107 1.007 1.005–1.009 28.4188 ,.0001
Parity 0.00268 0.000997 1.003 1.001–1.005 8.5068 0.0035
Number of abortions 0.00309 0.00118 1.004 1.001–1.005 8.7991 0.0030
Family history of BC 0.00265 0.00136 1.003 1.000–1.005 5.5983 0.0180
Sleeping status 20.00207 0.00104 0.998 0.996–1.000 4.9675 0.0258
Period of night shifts 0.00342 0.00128 1.003 1.001–1.006 3.9365 0.0472
Living environment 0.00478 0.00153 1.005 1.002–1.008 8.5892 0.0034
Positive coping 20.00273 0.00163 0.997 0.994–1.000 3.5443 0.0598
Subjective support 20.0156 0.00222 0.985 0.980–0.989 6.0298 0.0141
Utility degree of social support 20.00207 0.000872 0.998 0.996–1.000 6.8619 0.0088
Family problems 0.00952 0.00223 1.010 1.005–1.014 14.1553 0.0002
doi:10.1371/journal.pone.0036497.t002
Table 3. Comparison of age and menopausal status in invasive breast cancer group and benign breast group.
Invasive BC group Benign breast group x2 P
Age #40 yr 11(17.5%) 13(18.6%) 0.1725 0.9965
41–45 yr 15(23.8%) 15(21.4%)
46–50 yr 13(20.6%) 15(21.4%)
51–55 yr 9(14.3%) 11(15.7%)
$56 yr 15(23.8%) 16(22.9%)
Postmenopausal state postmenopausal 42(66.7%) 47(67.1%) 0.0034 0.9535
premenopausal 21(33.3%) 23(32.9%)
doi:10.1371/journal.pone.0036497.t003
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cancer is related to some life events [19].
Insulin-like growth factors system (IGFs) is composed of three
ligands, namely, IGF-1, IGF-2, and insulin, which transmit their
signals through two paralagous receptor proteins located in the
plasma membrane: the type I IGF receptor and the insulin
receptor (IGF receptors). The IGF system is involved in
tumorigenesis and the proliferation, survival, and migration of
tumor cells. High circulating IGF-1 concentrations and low blood
IGF binding protein concentrations are a risk factor for several
types of cancer including breast cancer [6,20–21]. Elevated
circulating IGF-1 levels have been significantly associated with
an increased risk of breast cancer, while the evidence for IGF-2 is
less clear. IGF2, a growth-promoting, mitogenic and anti-
apoptotic factor, plays a key role in the initiation and progression
of several cancers [22]. The IGF-2, an imprinted gene with
paternal allele expressed and maternal allele silenced, is an
important autocrine growth factor in tumors due to its mitogenic
and antiapoptotic functions mediated by receptor, which is
suggestive of its role in the development of breast cancer [23]. A
number of studies have shown consistently the loss of imprint of
IGF-2, which are associated with increased risk of several cancers,
including those cutaneous melanoma, laryngeal squamous cell
carcinoma, human meningiomas and breast cancer [24–26].
Evidence from epidemiology studies on the association of IGFs
and risk for cancer development has been indicating a potential
role of IGFs in breast carcinogenesis [27]. A recent study claims
that loss of imprinting (LOI) of IGF-2 gene defines a molecular
subgroup of Wilms tumors that have a different pathologic
subtype, a later age of onset, and greater IGF-2 expression than
those without LOI [28].
In our study, Among the 63 cases of breast invasive ductal
cancer patients, 26 cases were positive for IGF2, and the rate of
IGF-2 gene expression in the invasive breast cancer was higher
than in the tumor-adjacent tissue. This observation supports the
findings of studies which also showed an increased expression of
IGF2 protein by IHC in BC [29–30]. The rate of IGF-2 gene
expression in cases with lymph node metastasis was higher than in
patients without lymph node metastasis. The grade of tumor
pathology was higher, while the rate of IGF-2 gene expression was
also higher. The difference in different grades was statistically
significant. The outcomes have shown that IGF-2 may play
important role in the invasive growth and evolution of tumor. The
IGF-2 can promote the synthesis of calcium sticky protein, fiber
connection protein, laminnin and other adhesion molecules of
which their functions can increase its endothelium basement
membrane adhesion. The insulin-like growth factor-II(IGF-2) is a
potent mitogen that plays an essential role not only in normal
growth and development, but also in breast cancer susceptibility,
growth and progression by signalling the IGF1 and insulin
receptors [31–35] .The proliferation of breast cancer cells in
culture is also responsive to insulin-like growth factors, and
Figure 1. Shows the expression of IGF-2 in different tissues. Figure 1A : Shows the expression of IGF-2 in the invasive breast cancer tissue.
Figure 1B: Shows the expression of IGF-2 in the tumor –adjacent tissue. Figure 1C : Shows the expression of IGF-2 in the benign breast lesion tissue.
doi:10.1371/journal.pone.0036497.g001
Table 4. The comparison of IGF-2 expression in breast cancer and the adjacent tissues.
Types of tissue IGF2 expression x2 P
Negative N (%) Positive N (%)
Breast cancer tissue 37(58.7) 26(41.3) 13.35* 0.0003
Tumor-adjacent tissue 52(88.1) 7(11.9) 4.37n 0.0365
Benign breast lesions 53(75.7) 17(24.3) 3.26m 0.0709
Total 89(73.0) 33(27.0)
*Comparison between the first group and the second group.
nComparison between the first group and the third group.
mComparison between the second group and the third group.
doi:10.1371/journal.pone.0036497.t004
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by both breast tumors and cultured breast cancer cells. Based on
this explanation, it can be concluded that the expression of IGF-2
gene in invasive BC is related to the transfer of tumor.
In this study we observed a positive association between IGF-2
and the estrogen receptor. Recently, insulin and IGF have been
associated with regulation of sex hormone binding globulin, which
modifies the availability of estrogen [36]. Estradiol increased
insulin receptor substrate-1 mRNA and protein levels at concen-
trations consistent with a mechanism involving the estrogen
receptor. Almost all members of the IGF system are regulated by
the transcriptional level of ER. At the same time, ER can regulate
the transcription of IGF1, IGF2, IGF-1R, and IGF-BP [37]. In the
study, the results showed that the expression of IGF-2 in ER-
positive BC tissues was significantly higher than in ER-negative
BC tissues. This further confirms that the expression of IGF-2
positively correlated to the expression of ER in BC tissue. The
study found that the expression of IGF-2 was related to histological
grade, lymph node metastasis and ER status. Therefore, it implies
that IGF-2 may have certain significance for the treatment and
prognosis of breast cancer.
The following limitations might have affected the results of our
study. Firstly, inaccuracy in estimating BMI. Data on weight and
height, which were used to calculate BMI, were based on self-
reports and might not reflect the true values. Another potential
limitation is recall bias, it is possible that our subjects underre-
ported or over reported some information in their response to the
questionnaire however, if recall bias was present in our study
population, we believe that it acted similarly among cases and
controls.
Conclusion
The incidence of breast cancer is a result of multiple factors,
such as BMI, vocation, menstruation disorder, family history of
breast cancer, lifestyle and other pyscho-social factors. IGF-2 is
involved in the development of breast cancer, and its expression
rate is not the same in different tissues. It is therefore important for
women, to reduce negative life events and negative emotional
responses. Women should be encouraged to increase the use of
social support in order to antagonize the negative impact of life
events that can predispose them to breast cancer. Further studies
are required to explore the role of IGF-2 in breast cancer
development and progression. Health workers should encourage
women to comply with recommended breast cancer screening so
that exposure to risk factors is detected treated in time.
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